stockportfolio.pro
Stocks / JANX vs PHAT
JANX vs PHAT
Janux Therapeutics, Inc. and Phathom Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Janux Therapeutics, Inc. (JANX) | Phathom Pharmaceuticals, Inc. (PHAT) | |
|---|---|---|
| Market cap | $0.8B | $0.8B |
| Revenue (latest FY) | $10.00M | $175.11M |
| Net income (latest FY) | $-113.63M | $-221.25M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | -1136.3% | -126.3% |
| Return on equity | -11.9% | 50.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open JANX — free Open PHAT — freeFrequently asked questions
Which is bigger, JANX or PHAT?
Janux Therapeutics, Inc. is larger by market capitalization — $0.8B versus $0.8B.
Which grows faster, JANX or PHAT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.